Advertisement
UK markets close in 4 hours 29 minutes

  • FTSE 100

    8,069.44
    +45.57 (+0.57%)
     

  • FTSE 250

    19,731.58
    +132.19 (+0.67%)
     

  • AIM

    753.44
    +4.26 (+0.57%)
     

  • GBP/EUR

    1.1589
    +0.0001 (+0.01%)
     

  • GBP/USD

    1.2352
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    53,642.86
    +143.16 (+0.27%)
     

  • CMC Crypto 200

    1,424.84
    +10.08 (+0.71%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    81.73
    -0.17 (-0.21%)
     

  • GOLD FUTURES

    2,318.90
    -27.50 (-1.17%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,053.74
    +192.94 (+1.08%)
     

  • CAC 40

    8,091.21
    +50.85 (+0.63%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Global Rheumatoid Arthritis Clinical Trial Pipeline Report 2021: Clinical Trial Stages, Drug Mechanism Classes, Companies, Short-term Launch Highlights

Research and Markets
·2-min read

Dublin, May 28, 2021 (GLOBE NEWSWIRE) -- The "Global Rheumatoid Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Rheumatoid Arthritis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Rheumatoid Arthritis market. It covers emerging therapies for Rheumatoid Arthritis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Rheumatoid Arthritis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Rheumatoid Arthritis pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Rheumatoid Arthritis pipeline products by the company.

Short-term Launch Highlights:
Find out which Rheumatoid Arthritis pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Rheumatoid Arthritis phase 3 clinical trial pipeline products

  • Rheumatoid Arthritis phase 2 clinical trial pipeline products

  • Rheumatoid Arthritis phase 1 clinical trial pipeline products

  • Rheumatoid Arthritis preclinical research pipeline products

  • Rheumatoid Arthritis discovery stage pipeline products

  • Rheumatoid Arthritis pipeline products short-term launch highlights

Key Topics Covered:

1. Rheumatoid Arthritis Pipeline by Stages

2. Rheumatoid Arthritis Phase 3 Clinical Trial Insights

ADVERTISEMENT

3. Rheumatoid Arthritis Phase 2 Clinical Trial Insights

4. Rheumatoid Arthritis Phase 1 Clinical Trial Insights

5. Rheumatoid Arthritis Preclinical Research Insights

6. Rheumatoid Arthritis Discovery Stage Insights

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/cj9chl

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900